H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Biocryst Pharmaceuticals on Friday, setting a price target of $14, which is approximately 33.72% above the present share price of $10.47.
Fein expects Biocryst Pharmaceuticals to post earnings per share (EPS) of -$0.26 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in BioCryst (NASDAQ:BCRX), with an average price target of $12.5.
The analysts price targets range from a high of $16 to a low of $9.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $6.1 million and a net profit of -$42.86 million. The company's market cap is $1.85 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 54.20% success rate.
BioCryst Pharmaceuticals , Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.